PMID- 38290611
OWN - NLM
STAT- MEDLINE
DCOM- 20240311
LR  - 20240311
IS  - 1879-0720 (Electronic)
IS  - 0928-0987 (Linking)
VI  - 195
DP  - 2024 Apr 1
TI  - Application of nanofiber-based drug delivery systems in improving anxiolytic 
      effect of new 1,2,3-triazolo-1,4-benzodiazepine derivatives.
PG  - 106712
LID - S0928-0987(24)00023-X [pii]
LID - 10.1016/j.ejps.2024.106712 [doi]
AB  - Anxiety disorders are highly prevalent worldwide and can affect people of all 
      ages, genders and backgrounds. Much efforts and resources have been directed at 
      finding new anxiolytic agents and drug delivery systems (DDSs) especially for 
      cancer patients to enhance targeted drug delivery, reduce drug adverse effects, 
      and provide an analgesic effect. The aim of this study was (1) to design and 
      develop novel nanofiber-based DDSs intended for the oral administration of new 
      1,2,3-triazolo-1,4-benzodiazepines derivatives, (2) to investigate the physical 
      solid-state properties of such drug-loaded nanofibers, and (3) to gain knowledge 
      of the anxiolytic activity of the present new benzodiazepines in rodents in vivo. 
      The nanofibers loaded with 1,2,3-triazolo-1,4-benzodiazepine derivatives were 
      prepared by means of electrospinning (ES). Field-emission scanning electron 
      microscopy and attenuated total reflection Fourier transform infrared (ATR-FTIR) 
      spectroscopy were used for the physicochemical characterization of nanofibers. 
      The anxiolytic activity of new derivatives and drug-loaded nanofibers was studied 
      with an elevated plus maze test and light-dark box test. New 
      1,2,3-triazolo-1,4-benzodiazepine derivatives showed a promising anxiolytic 
      effect in mice with clear changes in behavioral reactions in both tests. The 
      nanofiber-based DDS was found to be feasible in the oral delivery of the present 
      benzodiazepine derivatives. The nanofibers generated by means of ES presented the 
      diameter in a nanoscale, uniform fiber structure, capacity for drug loading, and 
      the absence of defects. The present findings provide new insights in the drug 
      treatment of anxiety disorders with new benzodiazepine derivatives.
CI  - Copyright (c) 2024. Published by Elsevier B.V.
FAU - Botsula, Iryna
AU  - Botsula I
AD  - National University of Pharmacy, Kharkiv, Ukraine.
FAU - Ssmall es, Cyrillichavikin, Johannes
AU  - Ssmall es, Cyrillichavikin J
AD  - Electronics Research Laboratory, Department of Physics, University of Helsinki, 
      Helsinki, Finland.
FAU - Heinamaki, Jyrki
AU  - Heinamaki J
AD  - Institute of Pharmacy, Faculty of Medicine, University of Tartu, Tartu, Estonia. 
      Electronic address: jyrki.heinamaki@ut.ee.
FAU - Laidmae, Ivo
AU  - Laidmae I
AD  - Institute of Pharmacy, Faculty of Medicine, University of Tartu, Tartu, Estonia.
FAU - Mazur, Maryna
AU  - Mazur M
AD  - Division of Chemistry of Functional Materials, State Scientific Institution 
      "Institute for Single Crystals" of National Academy of Sciences of Ukraine, 
      Kharkiv, Ukraine.
FAU - Raal, Ain
AU  - Raal A
AD  - Institute of Pharmacy, Faculty of Medicine, University of Tartu, Tartu, Estonia.
FAU - Koshovyi, Oleh
AU  - Koshovyi O
AD  - National University of Pharmacy, Kharkiv, Ukraine; Institute of Pharmacy, Faculty 
      of Medicine, University of Tartu, Tartu, Estonia.
FAU - Kireyev, Igor
AU  - Kireyev I
AD  - National University of Pharmacy, Kharkiv, Ukraine.
FAU - Chebanov, Valentyn
AU  - Chebanov V
AD  - Division of Chemistry of Functional Materials, State Scientific Institution 
      "Institute for Single Crystals" of National Academy of Sciences of Ukraine, 
      Kharkiv, Ukraine; Department of Chemistry, V. N. Karazin Kharkiv National 
      University, Kharkiv, Ukraine.
LA  - eng
PT  - Journal Article
DEP - 20240128
PL  - Netherlands
TA  - Eur J Pharm Sci
JT  - European journal of pharmaceutical sciences : official journal of the European 
      Federation for Pharmaceutical Sciences
JID - 9317982
RN  - 0 (Anti-Anxiety Agents)
RN  - M4Z88L5FCM (Bz-423)
RN  - 12794-10-4 (Benzodiazepines)
RN  - 0 (Hypnotics and Sedatives)
RN  - 0 (Anticonvulsants)
SB  - IM
MH  - Humans
MH  - Female
MH  - Male
MH  - Mice
MH  - Animals
MH  - *Anti-Anxiety Agents
MH  - *Nanofibers/chemistry
MH  - Benzodiazepines
MH  - Hypnotics and Sedatives
MH  - Anticonvulsants
MH  - Drug Delivery Systems
OTO - NOTNLM
OT  - Anxiolytic agent
OT  - Benzodiazepine derivative
OT  - Electrospinning
OT  - Nanofiber-based drug delivery
OT  - Oral administration
COIS- Declaration of competing interest The authors declare no conflict of interest, 
      financial or otherwise.
EDAT- 2024/01/31 00:42
MHDA- 2024/03/11 06:42
CRDT- 2024/01/30 19:18
PHST- 2023/09/28 00:00 [received]
PHST- 2024/01/10 00:00 [revised]
PHST- 2024/01/27 00:00 [accepted]
PHST- 2024/03/11 06:42 [medline]
PHST- 2024/01/31 00:42 [pubmed]
PHST- 2024/01/30 19:18 [entrez]
AID - S0928-0987(24)00023-X [pii]
AID - 10.1016/j.ejps.2024.106712 [doi]
PST - ppublish
SO  - Eur J Pharm Sci. 2024 Apr 1;195:106712. doi: 10.1016/j.ejps.2024.106712. Epub 
      2024 Jan 28.